LAS VEGAS, Jan. 26, 2026 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced its participation in the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, held January 25-27, 2026, in Igls, Austria. As a leader in immunosuppression-free cell therapy solutions, Avant is actively evaluating advanced cells for potential application in a diabetes therapy at this premier European event.
This excerpt is quoted from the original release. Read the full announcement on PRNewsWire.
Brief Summary
At the 15th Annual EPITA Symposium, Avant Technologies is showcasing its commitment to innovation in diabetes therapy. The company, which focuses on cutting-edge cell-based therapies, aims to revolutionize treatment options.
- Avant Technologies (OTCQB: AVAI) presents at a key European event.
- Focus on immunosuppression-free cell therapy.
- Evaluation of advanced cells for diabetes therapy.
- Positioning to lead in diabetes treatment innovation.
Why it matters: With the growing prevalence of diabetes, advancements in effective therapies like these could significantly impact patient outcomes and the biotechnology market.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by PRNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.